Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Share-based Compensation: 2016-2025

Historic Share-based Compensation for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $3.0 million.

  • UroGen Pharma's Share-based Compensation fell 13.24% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 2.30%. This contributed to the annual value of $13.1 million for FY2024, which is 40.28% up from last year.
  • UroGen Pharma's Share-based Compensation amounted to $3.0 million in Q3 2025, which was up 10.76% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Share-based Compensation peaked at $6.2 million during Q1 2021, and registered a low of $2.2 million during Q2 2023.
  • Over the past 3 years, UroGen Pharma's median Share-based Compensation value was $2.8 million (recorded in 2024), while the average stood at $2.8 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first crashed by 55.80% in 2022, then spiked by 60.22% in 2024.
  • Over the past 5 years, UroGen Pharma's Share-based Compensation (Quarterly) stood at $5.4 million in 2021, then crashed by 55.80% to $2.4 million in 2022, then climbed by 10.30% to $2.6 million in 2023, then grew by 26.45% to $3.3 million in 2024, then declined by 13.24% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $2.7 million for Q2 2025, and $3.1 million during Q1 2025.